Publication | Closed Access

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Neuro-oncologyOncologySingle-agent BevacizumabMetronomic TherapyClinical TrialsBelob TrialPharmacotherapyNeurologyHigh-grade GliomasCancer TreatmentRecurrent GlioblastomaMedicineGlioma